-- 据周三提交给香港交易所的文件显示，联合实验室国际（HKG:3933）旗下珠海联合生物制药有限公司已获得中国国家药品监督管理局批准，开展度普利尤单抗生物类似药的临床试验。 该药物获批的适应症为特应性皮炎。
Related Articles
Asia
Joyvio Food's Loss Narrows 96% in Q1
Joyvio Food's (SHE:300268) attributable loss narrowed 96% to 7.84 million yuan in the first quarter from 180.9 million yuan in the year-ago period, according to a Monday filing by parent company Legend Holdings (HKG:3396) with the Hong Kong bourse.Loss per share at the Chinese agricultural products company came in at 0.0450 yuan compared with 1.0385 yuan in the prior-year period.Revenue declined 71% to 194.3 million yuan from 677.5 million yuan in the year-ago period.
$HKG:3396$SHE:300268
Asia
Shengyi Technology's 2025 Profit Surges 92%, Revenue Up 39%
Shengyi Technology (SHA:600183) posted full-year attributable net profit of 3.33 billion yuan in 2025, up 92% from 1.74 billion yuan in 2024.Earnings per share rose to 1.38 yuan from 0.73 yuan, according to a filing with the Shanghai bourse over the weekend.The electronic components manufacturer's revenue climbed 39% year over year to 28.4 billion yuan from 20.4 billion yuan.
$SHA:600183
Asia
East Money Information's Q1 Profit Up 38%, Revenue Rises 44%
East Money Information (SHE:300059) posted first-quarter attributable net profit of 3.74 billion yuan, up 38% from 2.72 billion yuan the previous year.Earnings per share rose to 0.2364 yuan from 0.1719 yuan, according to a filing with the Shenzhen bourse over the weekend.The financial services provider's operating revenue climbed 44% year over year to 5.03 billion yuan from 3.49 billion yuan.
$SHE:300059